Alterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in Italy June 23, 2022August 16, 2022
Prana’s Anti-Parkinsonian compound PBT434 presented at 13th International Conference for Alzheimer’s & Parkinson’s Diseases March 30, 2017August 16, 2022